Edison Oncology Reports Promising Interim Data from Ongoing Orotecan® Clinical Trial for Recurrent P

MENLO PARK, Calif., April 8, 2024 /PRNewswire/ -- Edison Oncology Holding Corp. ("Edison Oncology"), a privately held biopharmaceutical company, today announced ... Read more

Bron:

Health